Business Wire

Steadybit Launches the First MCP Server for Chaos Engineering, Bringing Experiment Insights to LLM Workflows

30.6.2025 13:03:00 CEST | Business Wire | Press release

Share

The Steadybit MCP Server enables organizations to use AI to reveal reliability gaps and surface new insights on experiment results

Steadybit GmbH, the leader in chaos engineering and reliability testing, announced today the launch of the new Steadybit MCP (Model Context Protocol) Server – the first AI-extensible solution for chaos engineering.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250630606346/en/

This MCP Server is a standardized way to connect Steadybit data to LLMs and AI workflows, enabling SRE teams to rapidly run analysis and generate insights about their system reliability and resilience. Recent high-profile outages across major cloud and security platforms highlight the tremendous cost of unexpected system failures.

As SRE teams work to improve their system reliability in an increasingly complex world, chaos engineering is the go-to strategy for making proactive improvements. AWS describes chaos engineering as a strategic necessity that is “essential for improving resilient systems”, and Gartner recommends chaos engineering for organizations as a critical resilience practice.

Bringing Chaos Engineering Into the AI Era

By running chaos experiments with Steadybit, teams are able to test and define the limits of their system resilience before incidents occur so they can mitigate risks and validate redundancies. With this new MCP, teams can easily pull data from their chaos experiments into their LLM workflows.

“Every team and tech stack works a little differently. We believe it’s important for a chaos engineering tool to be as easy to deploy and customize as possible, while maintaining the best-in-class features that make adoption across an enterprise seamless,” said Benjamin Wilms, CEO and Co-founder of Steadybit.

“With our new MCP, we are providing a new way for teams to work with their experiments to learn about their systems and improve their overall system resilience.”

By using all the data from past incidents, post-mortems, and completed experiments, the Steadybit MCP Server can help SRE teams uncover reliability learnings and take informed actions to improve their systems.

Prompt Examples Featuring the Steadybit MCP

With simple prompts, organizations using Steadybit for chaos engineering can now use LLM workflows in Claude, Gemini, or ChatGPT to get answers to questions like:

  • “We’ve been running experiments with Steadybit for a few months now. Can you create a report to summarize the experiment results since then for each team?”
  • “Review the types of experiments we have been running so far. Can you recommend a prioritized list of experiment types relevant to our systems that we have not yet run?”

When the Steadybit MCP is combined with other MCPs from observability and incident response tools, teams can then enter even more meaningful prompts, like:

  • “Since we have started running chaos experiments, please use metrics in PagerDuty to report the difference it has made on our MTTR and incidents.”
  • “Review recent incidents for Service A in Datadog. Can you suggest a few experiments we could run with Steadybit that would help us test and improve the service’s reliability?”

Introducing New Reliability Workflows for Teams

“As our teams test out different AI use cases, we can now directly connect data from Steadybit into any LLM workflows,” commented Krishna Palati, Director of Software Engineering at Salesforce. “This MCP will enable us to just type a prompt to pull custom reports, analyze reliability testing gaps, and get insights on what experiments to run next.”

Steadybit is on a mission to make it easier for teams to adopt and roll out chaos engineering at scale. With this latest release, Steadybit is making chaos engineering more accessible and empowering teams to innovate and learn with every experiment.

About Steadybit

Steadybit is the chaos engineering platform that makes it easy for organizations to proactively reveal reliability issues and train their operational resilience. With Steadybit, reliability and platform teams can quickly build, customize, and deploy experiments across their full tech stack using an intuitive no-code editor, flexible open source framework, and extensive automation capabilities.

With strong observability integrations, Steadybit enables teams to seamlessly optimize alerts, discover reliability gaps, and establish continuous verification of their systems. With this proactive approach to reliability, enterprises can confidently achieve service availability objectives, mitigate incidents, and deliver best-in-class services at scale.

To learn more, visit steadybit.com to request a demo or start a free trial today.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250630606346/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye